Pfizer withdraws OXBRYTA after post marketing studies showed that the risks of side effects were greater than the benefits.

Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.

This health news roundup covers significant advances and alerts, including the approval of Bristol Myers' new schizophrenia ...

Pfizer’s sudden market withdrawal of sickle cell therapy Oxbryta, which some analysts predicted would reach $750 million in ...

Agios Pharmaceuticals (AGIO) stock was downgraded at Leerink Partners on Pfizer's (PFE) recent decision to withdraw sickle ...

The U.S. Food and Drug Administration on Thursday alerted patients and healthcare professionals about the withdrawal of ...

This summary highlights major health news, including Bavarian Nordic's UNICEF agreement for mpox vaccines, Pfizer's ...

The company said benefits no longer outweighed the risks, with data suggesting the drug might increase the risk of pain ...

Pfizer has made the decision to withdraw Oxbryta (voxelotor), a treatment for sickle cell disease, from all markets where it is approved. Additionally, all clinical trials evaluating voxelotor, as ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

The EU's drug watchdog Thursday called for the suspension of approval for Pfizer's medicine to treat sickle cell disease, ...